KALA · KALA BIO, Inc. · Executive Compensation
$2.71
-0.31 (-10.28%)
At close · Nov 20
Return incl. dividend (before tax)
Q2 2022 earnings call transcript
Market Cap
$1.74M
Shares
644,660
Volume · Nov 20
19.23K
Avg daily vol (5 sessions)
17.3K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Todd Bazemore | Former Interim Chief Executive Officer, President and Chief Operating Officer | $3,476,972 |
| Kim Brazzell | Former Head of Research and Development and Chief Medical Officer | $1,358,174 |
| Mary Reumuth | Former Chief Financial Officer | $1,322,608 |
| Mark Iwicki | Former Chief Executive Officer | $906,642 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | Former Chief Executive Officer | $1,491,187 |
| Todd Bazemore | Former Interim Chief Executive Officer, Former President and Chief Operating Officer | $949,550 |
| Kim Brazzell | Head of Research and Development and Chief Medical Officer | $920,687 |
| Mary Reumuth | Former Chief Financial Officer | $778,269 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | Former Chief Executive Officer | $8,342,714 |
| Todd Bazemore | Former Interim Chief Executive Officer, Former President and Chief Operating Officer | $2,943,656 |
| Kim Brazzell | Head of Research and Development and Chief Medical Officer | $2,923,073 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | Chief Executive Officer | $1,868,299 |
| Todd Bazemore | President and Chief Operating Officer | $1,025,817 |
| Kim Brazzell | Head of Research and Development and Chief Medical Officer | $993,689 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | Chief Executive Officer | $2,772,056 |
| Todd Bazemore | President and Chief Operating Officer | $1,343,356 |
| Kim Brazzell | Head of Research and Development and Chief Medical Officer | $1,316,969 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
|
David Lazar
“Mr. Lazar’s resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2026-02-20 |
| Avi Minkowitz | Chief Financial Officer | Appointed | 2026-02-05 |
| Avi Minkowitz | Chief Executive Officer | Appointed | 2026-02-05 |
| David Lazar | Chief Financial Officer | Resigned | 2026-02-05 |
| David Lazar | Chief Executive Officer | Resigned | 2026-02-05 |
| David Lazar | Class II director | Appointed | 2026-02-02 |
|
Howard B. Rosen
“Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosen’s resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Company’s operations, policies or practices.”
|
Class III director | Resigned | 2026-02-02 |
|
C. Daniel Meyers
“Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosen's resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.”
|
Class III director | Resigned | 2026-02-02 |
|
Mark Iwicki
“Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosen's resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.”
|
Class II director | Resigned | 2026-02-02 |
|
Todd Bazemore
“Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosen's resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.”
|
Class II director | Resigned | 2026-02-02 |
|
Andrew I. Koven
“Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosen's resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.”
|
Class I director | Resigned | 2026-02-02 |
|
Marjan Farid
“Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosen's resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.”
|
Class I director | Resigned | 2026-02-02 |
|
Howard B. Rosen
“The resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
director | Resigned | 2025-12-29 |
|
Todd Bazmore
“The resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
director | Resigned | 2025-12-29 |
|
C. Daniel Myers
“The resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
director | Resigned | 2025-12-29 |
|
Mark Iwicki
“The resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
director | Resigned | 2025-12-29 |
|
Andrew I. Koven
“The resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
director | Resigned | 2025-12-29 |
|
Marjan Farid, M.D.
“The resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
director | Resigned | 2025-12-29 |
| David Lazar | Chairman of the Board of Directors | Appointed | 2025-11-25 |
| David Lazar | Board of Directors | Appointed | 2025-11-25 |
| Todd Bazemore | President and Chief Executive Officer | Terminated | 2025-10-20 |
| Todd Bazemore | Class II director | Appointed | 2025-09-02 |
| Todd Bazemore | Chief Executive Officer | Appointed | 2025-09-02 |
| Todd Bazemore | interim Chief Executive Officer and principal executive officer | Appointed | 2025-02-12 |
| Mark Iwicki | Chief Executive Officer | Resigned | 2025-02-12 |
Leadership
- Avi Minkowitz CEO, CFO, Board Member
- Todd Bazemore CEO, COO
- the Purchaser CEO, Chairman
- David Lazar Chairman, Board Member
- Eric L. Trachtenberg General Counsel
- Brendan Purdy Board Member
- Chaim (Dovi) Berger Board Member
- Hillel Posen Board Member
- Marjan Farid, M.D. Board Member
- Mark Blumenkranz Board Member
- Yonatan Colman Board Member
Key facts
CIK
1479419
CUSIP
483119301
13F (30d)
23 filings
19 filers
Visit website
Investor relations